QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. 会议论文 作者:  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano;  Ruff, Paul 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer 期刊论文 EUROPEAN JOURNAL OF CANCER, 2016, 卷号: 68 作者:  Price, Timothy;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano;  Ruff, Paul 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/06 Anti-EGFR therapy  Colorectal cancer  Gastrointestinal cancer  Panitumumab   Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文 作者:  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano;  Ruff, Paul 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/06 Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文 作者:  Price, Timothy Jay;  Newhall, Kathryn;  Peeters, Marc;  Kim, Tae Won;  Li, Jin 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/13 Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT 会议论文 作者:  Peeters, Marc;  Price, Timothy Jay;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/13 Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT. 会议论文 作者:  Price, Timothy Jay;  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/13 Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) 会议论文 作者:  Price, Timothy Jay;  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/13 Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文 作者:  Price, Timothy Jay;  Newhall, Kathryn;  Peeters, Marc;  Kim, Tae Won;  Li, Jin 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19 Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 期刊论文 LANCET ONCOLOGY, 2014, 卷号: 15, 期号: 6 作者:  Price, Timothy J.;  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/19 ASPECCT: A RANDOMISED, MULTICENTRE, OPEN-LABEL, PHASE 3 STUDY OF PANITUMUMAB VS CETUXIMAB FOR PREVIOUSLY-TREATED WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) 会议论文 作者:  Price, Tim J.;  Peeters, Marc;  Kim, Tae W.;  Li, Jin;  Cascinu, Stefano 收藏  |  浏览/下载：1/0  |  提交时间：2019/12/19